Forty Seven's IO Antibody Attracts Two Big Pharma Partners

Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.

Cancer-cells-pink-color_1200x675
More cancer combinations: Forty Seven to pair lead compound with PD-L1s

Californian biotech Forty Seven Inc. has caught the attention of two of Europe's biggest immuno-oncology players, Merck KGAA and Roche, both of which have signed deals to trial their approved PD-L1 inhibitors with Forty Seven's investigational CD47 antibody.

Forty Seven, a clinical-stage company focused on developing "next generation" IO treatments, announced both deals on Jan 11. The agreements...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer